An antibody produced in tobacco expressing a hybrid ß-1,4-galactosyltransferase is essentially devoid of plant carbohydrate epitopes

N-glycosylation of a mAb may have a major impact on its therapeutic merits. Here, we demonstrate that expression of a hybrid enzyme (called xylGalT), consisting of the N-terminal domain of Arabidopsis thaliana xylosyltransferase and the catalytic domain of human -1,4-galactosyltransferase I (GalT), in tobacco causes a sharp reduction of N-glycans with potentially immunogenic core-bound xylose (Xyl) and fucose (Fuc) residues as shown by Western blot and MALDI-TOF MS analysis. A radioallergosorbent test inhibition assay with proteins purified from leaves of WT and these transgenic tobacco plants using sera from allergic patients suggests a significant reduction of potential immunogenicity of xylGalT proteins. A mAb purified from leaves of plants expressing xylGalT displayed an N-glycan profile that featured high levels of galactose, undetectable xylose, and a trace of fucose. Hence, a transgenic plant expressing the hybrid GalT might yield more effective and safer monoclonals for therapeutic purposes than WT plants and even transgenic plants expressing the unchanged GalT.

Bibliographic Details

Main Authors:	Bakker, H., Rouwendal, G.J.A., Karnoup, A.S., Florack, D.E.A., Stoopen, G.M., Helsper, J.P.F.G., van Ree, R., van Die, I., Bosch, H.J.
Format:	Article/Letter to editor biblioteca
Language:	English
Subjects:	asparagine-linked oligosaccharides, desorption/ionization mass-spectrometry, developmental-stage, endoplasmic-reticulum, immunoglobulin-g, mannosidase-ii, n-glycans, rat-liver, substrate-specificity, transgenic plants,
Online Access:	https://research.wur.nl/en/publications/an-antibody-produced-in-tobacco-expressing-a-hybrid-ß-14-galactos
Tags:	Add Tag No Tags, Be the first to tag this record!